Press Release

August 11, 2026 TAKE/BSE/2026-27 TAKE/NSE/2026-27 The Manager The Manager-Listing Dept. of Corporate Services-Listing Department National Stock Exchange of BSE Limited, India Limited P. J. Towers, Dalal Street, Exchange Plaza, Bandra - Kurla Complex, Mumbai - 400001 Bandra (East), Mumbai - 400051 Script Code: 532890 Scrip: TAKE Script Id: TAKE Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sub: Press Release - TAKE Limited delivers strong Q1 FY27 Performance with Consolidated Revenue of ₹30.37 Cr and Net Profit of ₹ 1.06 Cr. Dear Sir / Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has issued a press release titled “TAKE Limited delivers strong Q1 FY27 Performance with Consolidated Revenue of ₹30.37 Cr and Net Profit of ₹ 1.06 Cr.” with respect to the financial results of the Company for the quarter ended June 30, 2026. A copy of the press release is enclosed herewith for your information and record. The same is also being made available on the website of the Company. You are requested to take the above cited information on your records. Thanking You, For TAKE Limited (Formerly known as TAKE Solutions Limited) Parmeshvar Dhangare Chairman & Director DIN: 11410125 TAKE LIMITED (formerly known as TAKE Solutions Limited) CIN: L72100TN2000PLC046338 Reg. Office Address: No. B3. No.9, B Block, Alsa Arcade, 3rd Floor, 2nd Avenue, Anna Nagar East, Chennai-600102, Tamil Nadu. Tel: 8108618322 E-mail: investorrelations@takelimited.com Website: www.takesolutions.com TAKE Limited delivers strong Q1 FY27 Performance with Consolidated Revenue of ₹30.37 Cr and Net Profit of ₹ 1.06 Cr. Strategic Entry into Biohacking, Science-Backed Nutraceuticals, and Digital Longevity Solutions. YoY Consolidated Revenue Finance Costs Drop 99.6% Consolidated Net Profit Surges to ₹30.37 Crore YoY to ₹0.07 Lakhs After Tax ₹1.06 Cr CHENNAI, August 11, 2026 — TAKE Limited, a global technology-driven healthcare company, today announced its unaudited financial results for the first quarter ended June 30, 2026 (Q1 FY 2026-27). Demonstrating significant operational momentum, the Company delivered Consolidated Revenue from Operations of ₹3,037.33 Lakhs (₹30.37 Crore) and a Consolidated Net Profit of ₹106.26 Lakhs (₹1.06 Crore), reversing a Net Loss of ₹(91.00) Lakhs in the corresponding prior-year period. KEY FINANCIAL PERFORMANCE HIGHLIGHTS (Q1 FY 2026-27) Consolidated Revenue & Total Income: Consolidated Revenue from Operations expanded dramatically to ₹3,037.33 Lakhs compared to Nil revenue in Q1 FY26. Total Income reached ₹3,170.11 Lakhs (₹31.70 Crore), backed by commercial scaling and execution. Profitability: Consolidated Profit Before Tax (PBT) and Net Profit After Tax (PAT) reached ₹106.26 Lakhs, marking a complete return to profitability compared to a Net Loss of ₹(91.00) Lakhs in Q1 FY26. Finance Costs: Finance costs plummeted by 99.62% YoY to just ₹0.07 Lakhs (down from ₹17.50 Lakhs in Q1 FY26), reflecting debt elimination, interest burden reduction, and a clean capital structure. Earnings Per Share (EPS): Basic and Diluted EPS turned positive at ₹0.07 per share (Face Value Re. 1/-), up from negative ₹(0.06) per share in Q1 FY26. Standalone Performance: Standalone Revenue from Operations surged to ₹1,196.90 Lakhs (vs ₹0.65 Lakhs in Q1 FY26), with Net Profit turning around to ₹96.83 Lakhs (vs a Net Loss of ₹216.45 Lakhs in Q1 FY26). STRATEGIC VISION: DISRUPTING THE LONGEVITY & ANTI-AGEING LANDSCAPE: Building on its restructured, lean balance sheet and deep heritage in life sciences, clinical research, and regulatory execution, TAKE Limited recently announced its strategic entry into India's rapidly accelerating Longevity, Biohacking, and Preventive Healthcare market. TAKE LIMITED (formerly known as TAKE Solutions Limited) CIN: L72100TN2000PLC046338 Reg. Office Address: No. B3. No.9, B Block, Alsa Arcade, 3rd Floor, 2nd Avenue, Anna Nagar East, Chennai-600102, Tamil Nadu. Tel: 8108618322 E-mail: investorrelations@takelimited.com Website: www.takesolutions.com Strategic Vectors & Market Opportunity: Expanding Addressable Market (TAM): The global longevity market is projected to grow from USD 27.61 Billion in 2025 to USD 67.03 Billion by 2035 (9.41% CAGR). In India, the preventive healthcare market reached USD 197 Billion in 2025, with anti-aging supplements expected to expand from USD 168.6 Million in 2025 to USD 341.4 Million by 2033 (9.5% CAGR) and anti-aging services reaching USD 1.06 Billion by 2035. Dual Business Model: TAKE Limited's strategy integrates science-backed nutraceuticals and biohacking consumer products with technology-enabled predictive digital tools to track and optimize metabolic health, sleep, cognition, and biological aging. High-Margin, Recurring Revenue Potential: The model focuses on high repeat-purchase consumer wellness categories, generating predictable, margin-accretive revenue streams while leveraging existing clinical capabilities for rapid regulatory validation. "Our Q1 FY27 results reflect the successful stabilization and revitalization of TAKE Limited's operational framework. With an extremely clean balance sheet, near-zero finance costs, and profitable operations, we are now executing our next growth phase. Our strategic entry into the Longevity and Anti-Ageing sector positions TAKE Limited at the intersection of life sciences, technology, and consumer wellness. By combining our regulatory and clinical domain expertise with cutting-edge biohacking and predictive digital tools, we are building a scalable, high-margin platform that addresses the multi-billion-dollar shift toward proactive health optimization." Parmeshvar Dhangare, Director, TAKE Limited. About TAKE Limited: TAKE Limited (Formerly known as TAKE Solutions Limited) is a global technology company delivering domain- intensive solutions and services for the life sciences and supply chain industries. With deep expertise in building scalable digital platforms and data-driven solutions, the company focuses on enabling enterprises to improve efficiency, compliance, and decision-making. Through its expanding investments in AI, analytics, and digital health technologies, TAKE Limited is positioning itself to participate in the next wave of innovation, ensuring its solutions address humancentric challenges across healthcare and other knowledge-led industries. TAKE LIMITED (formerly known as TAKE Solutions Limited) CIN: L72100TN2000PLC046338 Reg. Office Address: No. B3. No.9, B Block, Alsa Arcade, 3rd Floor, 2nd Avenue, Anna Nagar East, Chennai-600102, Tamil Nadu. Tel: 8108618322 E-mail: investorrelations@takelimited.com Website: www.takesolutions.com